LENZ Therapeutics (NASDAQ:LENZ) Sets New 12-Month High – What’s Next?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) reached a new 52-week high on Wednesday . The stock traded as high as $31.64 and last traded at $31.33, with a volume of 75050 shares. The stock had previously closed at $28.65.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Piper Sandler reiterated an “overweight” rating and set a $36.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, August 15th. Raymond James assumed coverage on shares of LENZ Therapeutics in a research report on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective on the stock. HC Wainwright assumed coverage on shares of LENZ Therapeutics in a research report on Monday, August 12th. They set a “buy” rating and a $38.00 price objective on the stock. Finally, William Blair upgraded shares of LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $35.40.

LENZ Therapeutics Stock Performance

The firm’s fifty day moving average price is $24.29 and its 200 day moving average price is $20.91.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.09. As a group, sell-side analysts predict that LENZ Therapeutics, Inc. will post -3.15 earnings per share for the current year.

Institutional Investors Weigh In On LENZ Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LENZ. American International Group Inc. acquired a new stake in shares of LENZ Therapeutics in the 1st quarter valued at $44,000. SG Americas Securities LLC acquired a new position in LENZ Therapeutics during the 3rd quarter worth $107,000. Marquette Asset Management LLC acquired a new position in LENZ Therapeutics during the 1st quarter worth $131,000. Squarepoint Ops LLC acquired a new position in LENZ Therapeutics during the 2nd quarter worth $181,000. Finally, GSA Capital Partners LLP acquired a new position in LENZ Therapeutics during the 3rd quarter worth $246,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.